Sucomet
Generic Name
Sitagliptin + Metformin Hydrochloride
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| sucomet 850 mg tablet | ৳ 5.00 | ৳ 50.00 |
Description
Overview of the medicine
Sucomet 850 mg tablet is a combination oral antidiabetic medication containing Sitagliptin and Metformin. It is used to improve glycemic control in adults with type 2 diabetes mellitus when diet and exercise alone do not provide adequate control, or when other antidiabetic agents are insufficient.
Uses & Indications
Dosage
Adults
The usual starting dose is one tablet (Sitagliptin 50 mg/Metformin 850 mg) orally twice daily with meals. Dosage should be individualized based on effectiveness and tolerability, not exceeding a maximum daily dose of 100 mg Sitagliptin and 2000 mg Metformin.
Elderly
Dosage adjustment may be necessary based on renal function assessment. Close monitoring of renal function is advised.
Renal_impairment
Contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73 m²). For moderate renal impairment (eGFR 30-59 mL/min/1.73 m²), lower doses may be used with caution and careful monitoring, often not exceeding 50 mg sitagliptin/1000 mg metformin daily.
How to Take
Take orally with meals to minimize gastrointestinal side effects associated with Metformin. Swallow the tablet whole with a glass of water; do not crush, break, or chew it.
Mechanism of Action
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the levels of active incretin hormones (GLP-1 and GIP). These hormones increase insulin synthesis and release from pancreatic beta cells and decrease glucagon secretion from pancreatic alpha cells, ultimately lowering blood glucose levels. Metformin is a biguanide that primarily decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. This combination works synergistically to improve glycemic control through complementary mechanisms.
Pharmacokinetics
Onset
Effects on glucose reduction are generally observed within a few hours of administration.
Excretion
Sitagliptin is primarily eliminated unchanged via renal excretion (active tubular secretion). Metformin is excreted unchanged in the urine.
Half life
Sitagliptin: Approximately 12.4 hours. Metformin: Approximately 4-9 hours (plasma elimination half-life).
Absorption
Sitagliptin is rapidly absorbed with Cmax typically within 1-4 hours. Metformin is slowly and incompletely absorbed, with Tmax around 2-3 hours.
Metabolism
Sitagliptin is minimally metabolized, primarily by CYP3A4 and CYP2C8. Metformin is not metabolized by the liver.
Side Effects
Contraindications
- •Hypersensitivity to sitagliptin, metformin, or any component of the formulation.
- •Severe renal impairment (eGFR < 30 mL/min/1.73 m²).
- •Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
- •Conditions associated with tissue hypoxia (e.g., cardiac failure, acute myocardial infarction, acute or chronic metabolic disease).
- •History of lactic acidosis.
- •Acute alcohol intoxication or chronic alcoholism.
- •Hepatic impairment.
Drug Interactions
Alcohol
Potentiates the effect of metformin on lactate metabolism and increases the risk of lactic acidosis.
Iodinated Contrast Agents
Temporary discontinuation of metformin is advised before or at the time of the procedure in patients undergoing iodinated contrast imaging procedures due to the risk of renal dysfunction and lactic acidosis.
Carbonic Anhydrase Inhibitors (e.g., Topiramate, Zonisamide)
May increase the risk of lactic acidosis.
Cationic drugs (e.g., Cimetidine, Propranolol, Furosemide, Nifedipine, Digoxin)
May increase metformin levels by competing for renal tubular transport.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.
Overdose
Metformin overdose can lead to lactic acidosis, which is a medical emergency. Sitagliptin overdose typically does not result in significant adverse effects. Management of overdose involves supportive care, correction of dehydration and acidosis, and hemodialysis for severe metformin overdose.
Pregnancy & Lactation
Generally not recommended during pregnancy or lactation due to insufficient human data. Use only if the potential benefit justifies the potential risk to the fetus or infant. Consult a doctor for advice.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Generally 2 to 3 years from the date of manufacture, specific details on packaging.
Availability
Pharmacies, hospitals, clinics
Approval Status
Approved by regulatory authorities (e.g., FDA, DGDA)
Patent Status
Patent expired for generic versions of Sitagliptin/Metformin
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
